Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 17 results for "om manchanda"

Expect Dr Lal PathLabs to surpass industry growth in FY17: CEO

CEO Om Manchanda expects planned expansion of central lab network in Kolkata and Lucknow will help Dr Lal PathLabs to sustain margins in FY17. Diagnostics space which has low penetration in India makes it a good pitch for companies like Dr Lal PathLab, ... Money Control, 2 weeks ago
Moneycontrol.com

Dr Lal PathLabs eyeing 18 pc growth in FY17

New Delhi, Jun 26 () Diagnostic services provider Dr Lal PathLabs is looking at around 18 per cent revenue growth this fiscal year as it undertakes initiatives to expand number of tests offered and its network across India. The company had posted a ...
 Times of India2 days ago Dr Lal PathLabs eyeing 18% growth in FY17  Moneycontrol.com1 day ago Dr Lal PathLabs eyeing 18 per cent growth in FY17  Economic Times2 days ago Dr Lal PathLabs CEO on expansion, competing with PE-backed players and more  VC Circle2 weeks ago
[x]  
DNA India

Ayush ministry raises curtains on international yoga day, stresses on the science behind yoga

Mass yoga demonstration in Chandigarh, an expected turnout of 25,000 to 30,000 people, seven points for demonstration of yoga across Delhi, and multiple events on various scales planned for the rest of the country and the world; the Ministry of ...
 DNA India2 weeks ago
Business Standard India

Diagnostics companies' premium might sustain

Diagnostic major Thyrocare Technologies, listed at a 49 per cent premium over its initial public offering (IPO) price of Rs 446 last Monday, is trading near Rs 630. The trend is similar to the one seen with Dr Lal PathLabs, which listed a few months ...
 Smart Investor1 month ago

Diagnostics companies' premium valuations may sustain

Thyrocare Technologies, the diagnostic major, listed at a 49% premium over its IPO price of Rs 446 last Monday and is now at Rs 630 levels. The trend is similar to the one seen with Dr Lal PathLabs which listed a few months back. Compared to the IPO ...
 Business Standard India1 month ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less